ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 221 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $320 | +19.0% | 58,720 | +46.6% | 0.00% | +100.0% |
Q2 2023 | $269 | -60.4% | 40,062 | -47.9% | 0.00% | -75.0% |
Q1 2023 | $679 | +207.2% | 76,854 | +165.4% | 0.01% | +166.7% |
Q4 2022 | $221 | -99.9% | 28,962 | +22.6% | 0.00% | +50.0% |
Q3 2022 | $168,000 | -59.0% | 23,623 | -53.4% | 0.00% | -50.0% |
Q2 2022 | $410,000 | +17.1% | 50,678 | +100.8% | 0.00% | +33.3% |
Q1 2022 | $350,000 | -47.8% | 25,239 | +5.7% | 0.00% | -25.0% |
Q4 2021 | $670,000 | +85.6% | 23,876 | +124.9% | 0.00% | +100.0% |
Q3 2021 | $361,000 | +15.7% | 10,614 | +38.8% | 0.00% | +100.0% |
Q2 2021 | $312,000 | -70.5% | 7,645 | -70.9% | 0.00% | -83.3% |
Q1 2021 | $1,059,000 | +789.9% | 26,301 | +1203.3% | 0.01% | +500.0% |
Q4 2020 | $119,000 | -77.7% | 2,018 | -81.6% | 0.00% | -66.7% |
Q3 2020 | $534,000 | +173.8% | 10,982 | +68.4% | 0.00% | +50.0% |
Q4 2019 | $195,000 | -73.1% | 6,520 | -56.5% | 0.00% | -60.0% |
Q2 2019 | $724,000 | – | 15,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
Triatomic Management LP | 102,889 | $560,745 | 0.39% |